Lindahl advises Q-linea AB on rights issue of units

The rights issue relates to units consisting of shares and warrants. Provided that the rights issue is fully subscribed for, Q-linea will receive approximately SEK 225 million before deduction of issue costs. The company may thereafter receive additional capital in May 2025 when the warrants issued are exercised for subscription of shares. The rights issue is covered up to approximately 81 percent by subscription and guarantee commitments.

Q-linea is a research, development and manufacturing company that primarily develops instruments and consumables for rapid infection diagnostics. The company's main product ASTar is a fully automated instrument that, using the consumables developed and manufactured by the company, can measure bacterial susceptibility to antibiotics. Q-linea's shares are listed on Nasdaq Stockholm Main Market.

Lindahl's team consists of Mattias Prage, Michaela Larsson and Olle Swärd Brattström.